Bio News
BlossomHill Therapeutics is pursuing an IPO worth $111.7 million (approximately 167.5 billion won) to develop a treatment for Tagrisso-resistant non-small cell lung cancer (NSCLC). Of the proceeds, $70 million will fund a phase 2 clinical trial of the EGFR-targeted molecule BH-30643. The remaining funds will be used for a phase 1 study of the acute myeloid leukemia treatment BH-30236 and to advance the pan-KRAS inhibitor BH-501284 into clinical development.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
